ASURAGEN, INC.
Austin, TX · CIK 0001358480 · Medtech · Acquired
Automated genotyping platform using deep learning to analyze PCR capillary electrophoresis traces for short tandem repeat (STR) disease diagnostics
- Grants
- $5.6M
- 16 awards
- Sector median: 1
- Raised
- $13M
- 2 Form D · Mar 2013
- 162 months since last filing
- Contracts
- $227K
- 7 awards · Health and Human S, Defense
- #445 of 4531 in medtech
- Patents
- 40
- 13 granted · 27 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2007200920112013201520172019
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal contract | Department of Health and Human Services · 00HCVGDB-2008-60583 - Armored Rna Quant Flue-b-ns Gene (CDC-4) | $30,000 | |
| Federal contract | Department of Health and Human Services · Luminex Lab Equipment | $52,200 | |
| Federal contract | Department of Health and Human Services · TAS::75 0943::TAS Armored Rna Quant | $8,535 | |
| Federal contract | Department of Health and Human Services · Armored Rna | $32,035 | |
| Private capital raised | Form D · SEC | $5,000,000 | |
| Federal contract | Department of Health and Human Services · Reagents | $16,000 | |
| Federal contract | Department of Health and Human Services · Rna Quandrant Reagents | $32,000 | |
| Private capital raised | Form D · SEC | $7,500,000 | |
| Federal contract | Department of Defense · Testing Interpretation | $56,250 | |
| Federal grant | Department of Health and Human Services · Phase II · Integrated Bioinformatics Analysis Suite for targeted NGS of clinical specimens | $263,998 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a reliable and standardized molecular assay for fragile x protein | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Quantitative Superplexing: Single-tube, many-target qPCR for cancer diagnostics | $246,864 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of an information-rich assay for C9ORF72 as a test for ALS and FTD | $619,938 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of an information rich assay for C ORF as a test for ALS and FTD | $1,379,750 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Development of a unified Alzheimer's disease test that combines high resolution analysis of TOMM40 and Apolipoprotein E for improved risk estimates | $224,984 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Development of a unified Alzheimer s disease test that combines high resolution analysis of TOMM and Apolipoprotein E for improved risk estimates | $224,984 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of an information-rich assay for C9ORF72 as a test for ALS and FTD | $759,812 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a unified information-rich test for CNBP and DMPK to improve assessment of Myotonic Dystrophy Type 1 and 2 | $224,978 | |
| Federal grant | Department of Health and Human Services · Phase I · Improving rare variant detection in next generation sequencing of liquid biopsies with a molecular barcoding technique that combines a novel primer structure and sophisticated bioinformatics methods | $224,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel strategies for enhanced analysis of repeat disorders | $224,999 | |
| Federal grant | Department of Health and Human Services · Phase I · A single test utilizing a unified multiplex PCR/CE workflow targeting five dominant inherited ataxias | $181,033 | |
| Federal grant | Department of Health and Human Services · Phase I · Single cell prenatal testing of circulating trophoblasts using a the novel immunomagnetic Micro-Aperture Chip (IMAC) system | $201,025 | |
| Federal grant | Department of Health and Human Services · Phase I · AmplideX DeepNet, a new paradigm for deep learning analytical tools in the molecular diagnostic space | $223,058 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Strategies for Enhanced Detection of Hemoglobinopathy Carriers | $231,153 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Strategies for Development of a Multiplexed Test with Expanded Content for Spinal Muscular Atrophy | $182,393 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 442 | Unlimited Tomorrow, Inc. | $237K | $6.7M |
| 443 | MicroMed, LLC | $237K | $950K |
| 444 | Maximum Fidelity Surgical Simulations, Inc. | $228K | $2.2M |
| 445 | ASURAGEN, INC. | $227K | $13M |
| 446 | HealthMyne, Inc. | $225K | $19M |
| 447 | WINDTREE THERAPEUTICS, INC. | $225K | — |
| 448 | DETON CORP | $225K | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Lyle ArnoldDirector
- Carol BerryExecutive Officer
- Rolland CarlsonDirector · Executive Officer
- Robert DominiciDirector
- Christopher EarlDirector
- Lynne HohlfeldExecutive Officer
- Evan MelroseDirector
- John MooneyDirector
- David RubinDirector
- David SargentDirector
- Ana WardExecutive Officer
- Matthew WinklerDirector · Executive Officer
Patents
- Methods Of Rna Amplificationgranted
- Methods For Nucleic Acid Size Detection Of Repeat Sequencesgranted
- Methods, Compositions, Kits, And Uses For Analysis Of Nucleic Acids Comprising Repeating A/t-rich Segmentsapplication
- Methods Of Rna Amplificationgranted
- Methods, Compositions, Kits, And Uses For Analysis Of Nucleic Acids Comprising Repeating A/t-rich Segmentsgranted
- Methods And Compositions For Amplicon Concatenationapplication
- Methods And Apparatuses For Improving Mutation Assessment Accuracyapplication
- Pcr Methods For Characterizing The 5' Untranslated Region Of The FMR1 And FMR2 Genesgranted
- Methods For Nucleic Acid Size Detection Of Repeat Sequencesapplication
- Methods And Compositions Involving Mirna And Mirna Inhibitor Moleculesapplication
- Methods And Compositions Involving Mirna And Mirna Inhibitor Moleculesgranted
- Methods And Compositions Involving Mirna And Mirna Inhibitor Moleculesgranted
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.